Forgot your password?

Forgot your username?

database > company
Velomedix
Medical Devices & Tech
1455 Adams Court, Suite 1016
Menlo Park, CA 940255 USA
phone:650-330-7314
fax:
Symbol Private
Founded 0
Employees
www.velomedix.com
Research Sector Medical Devices & Tech
Summary Description
Therapeutic hypothermia devices for patients patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury.
Management
John Dean, Chief Executive Officer; Griffeth Tully, M.D. Chief Medical Officer; Greg Hall, Ph.D.Vice President of Research & Development
Keywords
heart attack, stroke, cardiac arrest, therapeutic hypothermia

Comment | Printable Version | Modify profile |
Updated: Nov. 17, 2011

Description
Velomedix is a development stage medical device company created to realize the clinical potential of mild therapeutic hypothermia in benefiting patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury. Medical studies have consistently demonstrated that cooling protects cells at risk, prevents tissue death and preserves organ function. Accordingly, Therapeutic Hypothermia being developed by Velomedix provides a novel solution for the protection of the body�s organs during ischemic insults and later from reperfusion injury, as the cooling reduces oxygen metabolism, oxidative stress, microvascular clogging, free radical production, inflammation and maintains cell membrane integrity.
Technology / Differentiation
A comprehensive review of the medical literature demonstrates that cooling protects cells at risk, prevents tissue death and preserves organ function. Therapeutic Hypothermia offers a novel solution for the protection of the body?s organs during ischemic insults and later from reperfusion injury. Cooling protects tissue during ischemia by reducing oxygen metabolism, inflammation and maintaining cell membrane integrity. In the case of reperfusion injury hypothermia reduces oxidative stress, microvascular clogging, free radical production and inflammatory responses which are destructive to cells that have had blood flow restored after a period of ischemia.